Company Overview - Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and rare diseases [3] - The company's lead candidate, TARA-002, is an investigational cell-based therapy aimed at treating non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs) [3] - Protara is conducting ongoing Phase 2 trials for TARA-002 in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to Bacillus Calmette-Guérin (BCG) treatment, as well as in pediatric patients with LMs [3] Upcoming Events - Management will participate in a fireside chat at the TD Cowen 45 Annual Health Care Conference on March 5, 2025, at 9:50 am ET in Boston [1] - A live webcast of the fireside chat will be available on the company's website and will be archived for a limited time after the presentation [2] Additional Developments - Protara is also developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who cannot meet their choline needs through oral or enteral routes [3]
Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference